Dravet Syndrome Market Players:
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cadila Healthcare Ltd.
- Encoded Therapeutics Inc.
- Epygenix Therapeutics Inc.
- H Lundbeck AS
- Jazz Pharmaceuticals Plc
- Johnson and Johnson
- Lupin Ltd.
- PTC Therapeutics Inc.
- Stoke Therapeutics Inc.
- Supernus Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of dravet syndrome is evaluated at USD 639.37 million.
The market size for the dravet syndrome is projected to reach USD 1,584.5 million by the end of 2036, expanding at a CAGR of 9.5% during the forecast period, i.e., between 2027-2036.
The North America dravet syndrome market is expected to capture 39% share by 2036, driven by rising healthcare spending and R&D for Dravet syndrome treatments.
Key players in the market include Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc.
